Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Emibetuzumab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX163 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Emibetuzumab |
Emibetuzumab is a monoclonal antibody that has shown promising results in the treatment of various types of cancer. It specifically targets the c-Met protein, which is overexpressed in many types of cancer and plays a crucial role in tumor growth and metastasis. The Emibetuzumab ELISA Kit is a powerful tool that allows for the detection and measurement of Emibetuzumab in biological samples, providing valuable information for researchers and clinicians.
Emibetuzumab is a fully human IgG1 monoclonal antibody, meaning it is derived from human cells and has a constant region of the IgG1 isotype. This structure is important as it allows for a longer half-life in the body and a stronger binding affinity to its target, c-Met. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, each with a variable region that specifically binds to c-Met.
The main activity of Emibetuzumab is its ability to bind to c-Met and inhibit its function. c-Met is a receptor tyrosine kinase that is activated by its ligand, hepatocyte growth factor (HGF), and plays a crucial role in cell growth, survival, and migration. Overexpression of c-Met has been linked to tumor growth, invasion, and metastasis in various types of cancer. By binding to c-Met, Emibetuzumab blocks the binding of HGF and prevents the activation of downstream signaling pathways, ultimately inhibiting tumor growth and metastasis.
In addition to its inhibitory effects on c-Met, Emibetuzumab also has other mechanisms of action that contribute to its anti-tumor activity. It has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of tumor cells. Emibetuzumab also has the ability to block the formation of new blood vessels, known as angiogenesis, which is essential for tumor growth and survival.
The Emibetuzumab ELISA Kit is a valuable tool for researchers and clinicians studying the use of Emibetuzumab in cancer treatment. It allows for the detection and measurement of Emibetuzumab in various biological samples, such as serum, plasma, and tissue lysates. This information can be used to monitor the levels of Emibetuzumab in patients undergoing treatment and to assess the efficacy of the therapy.
The Emibetuzumab ELISA Kit can also be used in preclinical studies to determine the pharmacokinetics and pharmacodynamics of Emibetuzumab, providing valuable information for the development of new treatment strategies. Furthermore, the kit can be used to screen for potential drug-drug interactions and to assess the immunogenicity of Emibetuzumab in patients.
The Emibetuzumab ELISA Kit is a powerful tool for the detection and measurement of Emibetuzumab in biological samples. Its use in research and clinical settings allows for a better understanding of the structure, activity, and application of Emibetuzumab in cancer treatment. With its ability to specifically target c-Met and inhibit its function, Emibetuzumab shows great potential as a therapeutic antibody for various types of cancer. Ongoing studies and clinical trials will continue to explore the full potential of Emibetuzumab in the fight against cancer.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.